Laurus Labs Limited (BOM:540222)

Revance Therapeutics Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	1,442	1,417	484.6	759.4	484.6
Cash & Short-Term Investments	1,442	1,442	1,417	484.6	759.4	484.6
Cash Growth	1.81%	1.81%	192.30%	-36.19%	56.71%	2685.06%
Accounts Receivable	-	20,072	16,629	15,804	13,542	13,061
Other Receivables	-	58.6	86	153.3	-	389.7
Receivables	-	20,140	16,725	15,967	13,548	13,457
Inventory	-	19,365	18,454	16,848	17,603	15,755
Prepaid Expenses	-	292.8	280.5	204.5	166.4	164.5
Other Current Assets	-	2,083	1,474	1,112	1,369	887.9
Total Current Assets	-	43,323	38,350	34,617	33,446	30,749
Property, Plant & Equipment	-	43,160	40,475	37,002	32,086	22,772
Long-Term Investments	-	2,333	1,240	499	308.1	34.1
Goodwill	-	2,463	2,463	2,463	2,463	2,463
Other Intangible Assets	-	193.2	190.2	129.3	108.3	93.2
Other Long-Term Assets	-	1,884	1,152	1,894	1,269	1,396
Total Assets	-	93,356	83,870	76,604	69,680	57,507
Accounts Payable	-	9,585	10,512	7,107	8,764	11,787
Accrued Expenses	-	1,109	473.9	451.8	366.7	270.8
Short-Term Debt	-	17,150	13,893	9,958	9,107	8,861
Current Portion of Long-Term Debt	-	3,325	3,195	2,148	2,250	1,379
Current Portion of Leases	-	84.6	81.9	56.8	50	22.2
Current Income Taxes Payable	-	572	362.1	650	377	126.3
Other Current Liabilities	-	3,572	2,604	3,952	5,896	2,125
Total Current Liabilities	-	35,397	31,123	24,323	26,810	24,572
Long-Term Debt	-	6,456	7,982	7,614	5,963	4,292
Long-Term Leases	-	621.9	621.6	374.4	396.3	262.7
Long-Term Deferred Tax Liabilities	-	318.7	570.4	824.5	691.1	191.8
Other Long-Term Liabilities	-	3,865	1,824	2,471	1,777	1,790
Total Liabilities	-	47,331	42,715	36,117	36,090	31,500
Common Stock	-	1,079	1,078	1,077	1,075	1,073
Additional Paid-In Capital	-	7,328	7,171	7,131	7,013	6,948
Retained Earnings	-	36,265	33,150	33,020	26,250	18,833
Comprehensive Income & Other	-	53.8	-288.7	-852.7	-825.5	-878.3
Total Common Equity	44,726	44,726	41,110	40,375	33,512	25,976
Minority Interest	-	1,300	46.2	111.3	78.6	31.5
Shareholders' Equity	46,025	46,025	41,156	40,487	33,591	26,007
Total Liabilities & Equity	-	93,356	83,870	76,604	69,680	57,507
Total Debt	27,637	27,637	25,774	20,151	17,767	14,817
Net Cash (Debt)	-26,195	-26,195	-24,358	-19,666	-17,007	-14,332
Net Cash Per Share	-48.64	-48.55	-45.13	-36.45	-31.54	-26.63
Filing Date Shares Outstanding	539.8	539.25	538.97	538.65	537.36	536.6
Total Common Shares Outstanding	539.8	539.25	538.97	538.65	537.36	536.6
Working Capital	-	7,926	7,227	10,294	6,636	6,177
Book Value Per Share	82.94	82.94	76.27	74.96	62.36	48.41
Tangible Book Value	42,069	42,069	38,456	37,783	30,941	23,419
Tangible Book Value Per Share	78.01	78.01	71.35	70.14	57.58	43.64
Land	-	2,006	2,278	2,242	2,238	1,321
Buildings	-	15,624	13,665	11,757	8,641	7,602
Machinery	-	40,011	35,689	29,735	22,435	18,034
Construction In Progress	-	4,584	4,228	5,508	8,132	3,622

Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.